Evidence map›Paper›PMID 40777947›Full record

ArticleAfrican health sciences2024

The utility of Insulin Like Growth Factor Binding Proteins (IGFBPs-1, 2, 3) with genes expression in resistance to Imatinib and Nilotinib in chronic myeloid leukemia: a pilot study from Delta Egypt.

Nadia El Menshawy, Mohamed Sabry El-Ghonemy, Shaimaa El-Ashwah, Heidi Elkerdawy, Ramy Abbas, Mostafa Abdelhakiem, Maha Saif, Ahmed El-Sebaie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nadia El MenshawyHematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed Sabry El-GhonemyHematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Shaimaa El-AshwahClinical hematology unit, oncology center, Faculty of Medicine, Mansoura university, Egypt.
Heidi ElkerdawyClinical Hematology, Internal Medicine department, Faculty of Medicine, Port Said University, Port Said.
Ramy AbbasMedical oncology unit, Oncology Center, Faculty of Medicine, Mansoura university, Mansoura, Egypt.
Mostafa AbdelhakiemMedical oncology unit, Oncology Center, Faculty of Medicine, Mansoura university, Mansoura, Egypt.
Maha SaifMedical oncology unit, Oncology Center, Faculty of Medicine, Mansoura university, Mansoura, Egypt.
Ahmed El-SebaieHematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Resistance to tyrosine kinase inhibitors (TKIs) is an obstacle facing CML patients in spite of the high cure rate. In this context, a study association between IGFBP (1, 2, 3) genes expression and their proteins in CML with the response to TKI has been implicated. Patients and methods: 115 newly diagnosed CML in chronic phase (CP) followed up over 12 months under TKI. 116 apparently healthy individuals were used as a control. RT-qPCR amplification was used for detecting IGFBPs genes expression, and ELISA technique was used for measuring serum IGFBPs. Results: IGFBP-1 and IGFBP-3 genes expression, as well as their serum levels, were significantly higher in CML patients, whereas IGFBP-2 gene expression was not. Interestingly, IGFBP-1 gene expression and IGFBP-1 serum levels were significantly higher in resistant patients compared to responder patients. However, the expression of IGFBP-2, 3 genes and their serum were insignificant. Conclusion: IGFBP-1 gene expression and its serum were significantly correlated with resistance. It is currently recommended that IGF-receptor inhibitors be developed and utilized. We are hoping to optimize the cure rate for CML treated with TKIs.

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmImatinib MesylateInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsPyrimidinesAdolescentAdultEgyptFemaleGene ExpressionHumansAntineoplastic AgentsIGFBP1 protein, humanImatinib MesylateInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsnilotinibProtein Kinase InhibitorsPyrimidinesCMLGene expressionIGFBP-1-3ImatinibNilotinib

Identifiers

PMID40777947
PMCPMC12327122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.